Efficacy of rufinamide in drug-resistant epilepsy: a meta-analysis.

Abstract

Rufinamide is a new orally active antiepileptic drug that has been found to be effective in the treatment of partial seizures and drop attacks associated with Lennox-Gastaut syndrome. We performed a quantitative analysis of the efficacy of this new antiepileptic drug from all double-blind, add-on, randomized, placebo-controlled clinical trials published to date. Data from 918 patients were studied. The number of patients per study varied from 25 to 262. Rufinamide was efficacious in doses up to 45 mg/kg daily when provided as adjunctive therapy in patients with Lennox-Gastaut syndrome and other drug-resistant epilepsies. Further studies are needed to confirm and expand these findings.

• Authors: Alberto Verrotti, Giulia Loiacono, Enzo Ballone, Peter A Mattei, Francesco Chiarelli, Paolo Curatolo
• Journal: Pediatric neurology (Pediatr Neurol) Vol. 44 Issue 5 Pg. 347-9 (May 2011) ISSN: 1873-5150 [Electronic] United States
• PMID: 21481742 (Publication Type: Journal Article, Meta-Analysis, Randomized Controlled Trial)
• Copyright: Copyright © 2011 Elsevier Inc. All rights reserved.

Chemical References

• Anticonvulsants
• Triazoles
• rufinamide

Topics

• Anticonvulsants (therapeutic use)
• Chi-Square Distribution
• Dose-Response Relationship, Drug
• Double-Blind Method
• Epilepsy (drug therapy)
• Humans
• Odds Ratio
• Triazoles (therapeutic use)